DEST — Destiny Pharma Share News
0.000.00%
- £4.50m
- -£1.88m
RCS - Destiny Pharma PLC - FDA/CDC highlight need for infection preventions
AnnouncementREG - Destiny Pharma PLC - Director Disclosure
AnnouncementREG - Destiny Pharma PLC - Appointment of Corporate Broker
AnnouncementREG - Destiny Pharma PLC - Director Shareholding Amendment
AnnouncementREG - Destiny Pharma PLC - XF-73 advances to clinically enabling safety study
AnnouncementREG - Destiny Pharma PLC - Price Monitoring Extension
AnnouncementREG - Destiny Pharma PLC - Second Price Monitoring Extn
AnnouncementREG - Destiny Pharma PLC - Notice of R&D Update Meeting
AnnouncementREG - Destiny Pharma PLC - Interim results for six months ended 30 June 2022
AnnouncementREG - Destiny Pharma PLC - Positive update from EMA on NTCD-M3 Phase 3 plans
AnnouncementRCS - Destiny Pharma PLC - Presenting at HC Wainwright Investment Conference
AnnouncementREG - Destiny Pharma PLC - Expiry of Share Options
AnnouncementREG - Destiny Pharma PLC - Notice of Interim Results
AnnouncementREG - Destiny Pharma PLC - Chair’s Investor Update
AnnouncementREG - Destiny Pharma PLC - Publication of new data on NTCD-M3
AnnouncementREG - Destiny Pharma PLC - Positive update from US FDA on XF-73 Phase 3
AnnouncementREG - Destiny Pharma PLC - Grant from the Cystic Fibrosis Foundation
AnnouncementREG - Destiny Pharma PLC - Publication of XF-73 drug synergy data
AnnouncementREG - Destiny Pharma PLC - New XF-73 research programme
Announcement